JAT’s Golden Koala scores new supply agreement
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Golden Koala Group Pty Ltd — 51% owned subsidiary of Jat Energy (ASX:JAT) — has entered into a supply agreement with AustAgri Pty Limited.
Under the agreement, Golden Koala will supply its Golden Koala Premium Range Infant Formulas to AustAgri for sale in mainland China, Hong Kong, Macau and Taiwan, as well as via e-commerce platforms.
With Golden Koala Group Pty Ltd as supplier, and AustAgri (AA) as customer, the key terms of the agreement are as follows;
The Term: five years commencing 90 days after Golden Koala notifies AA that it has received approval for the products from the China Food and Drug Administration.
Exclusivity and territories: AA has been granted the exclusive right to distribute and sell the products in mainland China. It has the non-exclusive right to distribute and sell the products in Hong Kong, Macau and Taiwan.
E-Commerce: AA has the right to distribute and sell the products in mainland China and any other places via e-commerce channel only.
Products: the products are 900g tins of Golden Koala Premium Range Infant Formulas.
Minimum purchase quantities: AA must order a minimum amount of 900g tins annually in each of the five years of the agreement. The total revenue to be received by Golden Koala over five years from sales of minimum quantities will be approximately $98 million.
Guaranteed deposit: AA must pay Golden Koala A$1 million as a guaranteed deposit in two instalments. The first instalment is $500,000 to be paid within seven business days of signing the agreement and $500,000 within seven business days of being notified that CFDA approval has been granted for all products.
Payment terms: 50% is payable by AA at the time of order with the balance payable upon Golden Koala notifying AA that the products are ready for production.
However it is an early stage of JAT’s development so if considering this stock for your portfolio, you should take all public information into account and seek professional financial advice.
JAT announced the agreement on Friday afternoon, which led to the small cap’s shares closing the day almost 12% higher at 8.5 cents.
The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.
This news comes just weeks after JAT announced a major deal with Woolworths (ASX:WOW), which will see WOW offer NEURIO Formulated Milk Powder with Lactoferrin for sale to Chinese consumers via its flagship store on cross-border platform TMall Global from early August 2018.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
